Core Viewpoint - Taihe Cheng Medical (CCM) experienced a 2.4% increase in stock price, reaching $5.345 per share, with a total market capitalization of $26.52 million as of July 30 [1] Financial Performance - As of December 31, 2024, Taihe Cheng Medical reported total revenue of 384 million RMB, a year-on-year decrease of 28.55% [1] - The company recorded a net profit attributable to shareholders of -30.8 million RMB, reflecting a year-on-year decline of 3.56% [1] Company Overview - Taihe Cheng Medical Group Limited, listed on the New York Stock Exchange in 2009, is primarily engaged in medical services, focusing on cancer prevention, diagnosis, education, and research [1] - Established in 1997, the company provides third-party tumor imaging diagnosis and radiation therapy services, operates self-built cancer specialty hospitals, outpatient departments, independent imaging centers, and proton centers [1] Strategic Partnerships - In 2015, Taihe Cheng signed a long-term strategic cooperation agreement with the University of Texas MD Anderson Cancer Center, focusing on diagnostic technology, radiation quality control, medical processes, operational management, and brand usage in Singapore and mainland China [1] - The collaboration aims to develop an international cancer specialty hospital based on a multidisciplinary treatment model and clinical research, enhancing patient experience and improving cancer treatment standards in China [1]

Financial Performance - As of June 30, 2024, the total revenue of Taihe Cheng Medical (CCM) is 219 million RMB, representing a year-on-year decrease of 23.09% [1] - The net profit attributable to the parent company is -172 million RMB, showing a significant year-on-year decline of 89.33% [1] Company Overview - Taihe Cheng Medical Group Limited, listed on the New York Stock Exchange in 2009, is primarily engaged in medical services, focusing on cancer prevention, diagnosis, education, and research [2] - The company provides third-party tumor imaging diagnosis and radiation therapy services, operates specialized cancer hospitals, outpatient departments, independent imaging centers, and proton centers [2] - In 2015, Taihe Cheng signed a long-term strategic cooperation agreement with the University of Texas MD Anderson Cancer Center to enhance cancer treatment and research capabilities in China and Singapore [2]